OBEZİTE VE ADİPOKİNLER

Sedat Motor, Mukadder Canan Keskin, Recep Dokuyucu
2.144 428

Öz


Obesite yağ dokusunun aşırı artışı olarak
tanımlanır. Son yıllarda yapılan çalışmalar,
beyaz yağ dokusunun, adipokinler olarak
tanımlanan bir grup biyoaktif polipeptidi
üretip-sekrete edebilen endokrin bir organ
olduğunu ortaya çıkarmıştır. Yapılan bu
çalışmalarda adipokinlerin insülin direnci,
enflamasyon, hipertansiyon, kardiyovasküler
ve metabolik bozukluklar gibi obesite ile
ilişkili bir grup hastalığın gelişiminde önemli
role sahip olduğu gösterilmiştir. Bu derlemede
obezite ile ilgili tanımlanmış adipokinler,
sitokinler ve onların fonksiyonları hakkındaki
bilgiler verilmiştir.
Anahtar Kelimeler: Yağ dokusu, Obezite,
Adipokinler, Sitokinler


Anahtar kelimeler


Yağ dokusu, Obezite, Adipokinler, Sitokinler

Tam metin:

PDF


DOI: http://dx.doi.org/10.17944/mkutfd.16142

Referanslar


Dina C. New insights into the genetics of body weight. Curr Opin Clin Nutr Metab

Care 2008;11:378-384.

Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance and cardiovascular

disease. Recent Prog Horm Res 2004;59:207-223.

Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. Epidemiology and economic

impact of obesity and type 2 diabetes. Surg Clin North Am 2001;91:1163-1172

Türkiye Beslenme ve Sağlık Araştırması 2010. http://ekutuphane.sagem.gov.tr/kitaplar

Jacobi D, Stanya KJ, Lee CH. Adipose tissue signaling by nuclear receptors in

metabolic complications of obesity. Adipocyte 2012;1(1):4-12

Nadir I, Oğuz D. Adipokinler. Güncel Gastroenteroloji Dergisi. 2009; 13; 107-109.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional

cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.

Mehta S, Farmer JA. Obesity and inflamation: A new look at an old problem. Curr

Atheroscler Rep 2007;9:134-138.

Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of

adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and

subcutaneous adipose tissues of obese humans. Endocrinology 2004;14:52273-52282.

Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB

protein: evidence for a peripheral signal linking adiposity and central neural networks.

Science 1995;269:546-549.

Chen G, Koyama K, Yuan X, Lee Y, Zhou YT, O'Doherty R, Newgard CB, Unger

RH. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin

gene therapy. Proc Natl Acad Sci USA. 1996 10;93(25):14795-14799.

Orci L, Cook WS, Ravazzola M, Wang MY, Park BH, Montesano R, Unger RH.

Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad

Sci USA. 2004 17;101(7):2058-2063.

Vazquez-Vela MEF, Torres N, Tovar AR. White adipose tissue as endocrine organ

and its role in obesity. Arch Med Res 2008;39:715-728.

Coppari R, Bjorbaek C. Leptin revisited: its mechanisms of action and potential for

treating diabetes. Nat Rev Drug Discov 2012;11:692-708

Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley

GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory

immune responses. FASEB J 1998;12:57-65.

Konstantidines S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet

aggregation and arterial thrombosis suggests a mechanism of atherothrombotic disease

in obesity. J Clin Invest 2001;108:1533-1540.

Scherer PE, Williams S, Flogiano M, Baldini G, Lodish HF. A novel serum protein

similar to C1q, produced exclusively by adipocytes. J Biol Chem 1995;270:26746–

Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, et al.

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating

AMP-activated protein kinase. Nat Med 2002;8:1288-1295.

Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev

;26:439-451.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocytederived

plasma protein, adiponectin, suppresses lipid accumulation in class A

scavenger receptors expression in human monocyte-derived macrophages. Circulation

;103:1057-1063.

Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions

of adiponectin with the endocrine system and inflammatory parameters. J Clin

Endocrinol Metab 2003;88:2714-2718.

Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, Scherer PE. Adipose

tissue mass and location affect circulating adiponectin levels. Diabetologia

;54:2515-2524.

Juan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor

levels. A possible link between insulin resistance and atherothrombosis.

Diabetologia 1991;34:457-462.

Appel SJ, Harrell JS, Davenport ML. Central obesity, the metabolic syndrome and

plasminogen activator inhibitor-1 in young adults. J Am Acad Nurse Pract

;17:535-541.

Siklova-Vitkova M, Klimcakova E, Polak J, Kovacova Z, Tencerova M, Rossmeislova

L, et al. Adipose tissue secretion and expression of adipocyte-produced and

stromavascular fraction-produced adipokine vary during multiple phases of weightreducing

dietary intervention in obese women. J Clin Endocrinol Metab

;97:1176-1181.

Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL,

McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and

insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes.

;53(2):336-346.

Gurlek A, Bayraktar M, Kirazli S: Increased plasminogen activator inhibitor-1 activity

in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.

Diabetes Care. 2000;23(1):88-92.

Festa A, D’Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase

proteins and plasminogen activator inhibitor-1 predict the development of type 2

diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:1131-1137.

Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-

Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose

angiotensinogen is involved in adipose tissue growth and blood pressure regulation.

FASEB J 2001;15:2727-2729.

Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen

concentration and variants of the angiotensinogen gene in white and black children. J

Clin Invest. 1995;95(3):948-953.

Forrester T, McFarlane-Anderson N, Bennet F, Wilks R, Puras A, Cooper R, Rotimi

C, Durazo R, Tewksbury D, Morrison L. Angiotensinogen and blood pressure among

blacks: findings from a community survey in Jamaica. J Hypertens. 1996;14(3):315-

32. Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A, and

Cassis LA. Adipocyte-specific deficiency of angiotensinogen decreases plasma

angiotensinogen concentration and systolic blood pressure inmice. Am J Physiol

Regul Integr Comp Physiol 2012;302:R244-R251.

Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia

induced production of acute phase reactants in adipose tissue. J Biol Chem

;276:42077-42083.

Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich V, Coussieu

C, Gauthier E, Courtine M, Zucker JD, et al. Serum amyloid A: production by human

white adipocytes and regulation by obesity and nutrition. Diabetologia 2005;48:519-

Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, et

al. Serum amyloid A as a predictor of coronary heart disease and cardiovascular

outcome in women: the National Heart, Lung, and Blood Institute Sponsored

Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-732.

Ogasawara K, Mashiba S, Wada Y, et al. A serum amyloid A and LDL complex as a

new prognostic marker in stable coronary artery disease. Atherosclerosis

;174:349–56.

King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin

Lipidol 2011;22:302-307.

Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes.

Nature 2001;409:307-312.

Verma S, Li SH,Wang CH, et al. Resistin promotes endothelial cell activation: further

evidence of adipokine–endothelial interaction. Circulation 2003;108:736-740.

Kusminski CM, Meternan PG, Kumar S. Role of resistin in obesity, insülin resistance

and Type II diabetes. Clinical Science 2005;109:243-256.

Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a

lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res

;58:2359-2365.

Sanders PM, Tisdale MJ. Effect of zinc-α2-glycoprotein (ZAG) on expression of

uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 2004;212:71-

Gong FY, Zhang SJ, Deng JY, et al. Zinc-alpha2-glycoprotein is involved in

regulation of body weight through inhibition of lipogenic enzymes in adipose tissue.

Int J Obes 2009;33:1023-1030.

Yeung DCY, Lam KSL, Wang Y, Tso AW, Xu A. Serum zinc-α2-glycoprotein

correlates with adiposity, triglycerides, and the key components of the metabolic

syndrome in Chinese subjects. J Clin Endocrinol Metab 2009;94:2531-2536.

Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently

improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res

;65:73-82.

Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insülin and

glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept 2005;132:27-32.

Yu S, Zhang Y, Li MZ, et al. Chemerin and apelin are positively correlated with

inflammation in obese type 2 diabetes patients. Chin Med J 2012;125:3440-3444.

Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly

expressed in visceral than in subcutaneous adipose tissue and is a marker of intraabdominal

obesity fat mass. Cell Metab 2007;6:79-87.

Graham TE, Yang Q, Bluher M, et al. Retinol binding protein 4 contributes to insülin

resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563.

Hammarstedt A, Graham TE, Kahn BB. Adipose tissue dysregulation and reduced

insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells.

Diabetol Metab Syndr 2012 19;4(1):42. doi: 10.1186/1758-5996-4-42.

Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease

inhibitor: a unique insulin-sensititizing adipocytokine in obesity. Proc Natl Acad Sci

USA 2005;102:10610-10615.

Chang HM, Lee HJ, Park HS, et al. Effects of weight reduction on serum vaspin

concentrations in obese subjects: modifications by insulin resistance. Obesity

;18:2105-2110.

Kloting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces

food intake and has sustained blood glucose-lowering effects. Diabetologia

;54:1819-1823.

Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral

fat that mimics the effects of insulin. Science 2005;307:426-430.

Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity type

diabetes mellitus insulin resistance, metabolic syndrome and cardiovascular

diseases: a meta-analysis and systematic review. Diabetes Metab Res Rev

;27:515-527.

Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression

through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys

Acta 2008;1783:886-895.

Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific

adipokine in human adipose tissue: possible role in modulating insulin action. Am J

Physiol Endocrinol Metab 2006;290:E1253-1261.

Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-α-induced expression

of adhesion molecules in endothelial cells via ERK/NF-kB pathway. Biochem

Biophys Res Commun 2012;425:406-410.

Zhong X, Zhang HY, Tan H, et al. Association of serum omentin-1 levels with

coronary artery disease. Acta Pharmacol Sin 2011;32:873878.

Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigenpresenting

cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp

Med 2003;198:977-985.

Goralski KB,McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that

regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-

62. Takahashi M, Takahashi Y, Takahashi FN, et al. Chemerin enhances insulin signaling

and potentiates insulin-stimulated glucose uptake in 3T3-L1adypocytes. FEBS Lett

;582:573-578.

Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor

inducing insulin resistance in primary human skeletal muscle cells. Diabetes

;58:2731-2740.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a

growth hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9; 402

(6762): 656-60.

Aydoğan A, Akküçük S, Özkan OV, Aydın M, Motor S, Uğur M, Oruç C, Yönden Z.

The Protective Effects Of Peptide YY And Ghrelin In Acute Biliary Pancreatitis. Acta

Medica Mediterranea, 2014, 30(2): 323-327

Der Lely A.J, Ghigo E. Non-acylated ghrelin counteracts the metabolic but not the

neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab

;89: 3062-3065.

Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived

factor with potent neuronal differentiative activity. Experimental eye research.

;53(3):411-4.

Yüksel R. Homozigot Hbss Erişkin Orak Hücre Anemili Hastalarda Serum PEDF

Düzeyleri ile hsCRP Arasındaki ilişkinin incelenmesi. Uzmanlık Tezi, Hatay: Mustafa

Kemal Üniversitesi Tayfur Ata Sökmen Tıp Fakültesi, Tıbbi Biyokimya AD, 2014

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW.

Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest

;112:1796-1808.

Lumeng C, Bodzin J, Saltiel A. Obesity induces phenotypic switch in adipose tissue

macrophage polarization. J Clin Invest 2007;117:175-184.

Lorenzo M, Fernandez-Veledo S, Vila-Bedmar R, et al. Insulin resistance induced by

tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci

;86:E94-104.

Romanatto T, Roman EA, Arruda AP, et al. Deletion of the tumor necrosis factor-α

receptor 1 (TNFR1) protects against diet-induced obesity by means of increased

thermogenesis. J Biol Chem 2009;284:36213-36222.

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis

factor-alpha: direct role in obesity linked-insulin resistance. Science 1993;259:87-91.

Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissuederived

cytokines: in vivo and in vitro investigations in humans. Am J Physiol

Endocrinol Metab 2003;285:E257-533.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.